Giuseppe Boriani1, Marco Proietti2, Cécile Laroche3, Laurent Fauchier4, Francisco Marin5, Michael Nabauer6, Tatjana Potpara7,8, Gheorghe-Andrei Dan9, Zbigniew Kalarus10, Igor Diemberger11, Luigi Tavazzi12, Aldo P Maggioni3,13, Gregory Y H Lip2,14. 1. Cardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo, 71, 41124 Modena, Italy. 2. Institute of Cardiovascular Sciences, University of Birmingham, Dudley Road, B18 7QH Birmingham, UK. 3. EURObservational Research Programme Department, European Society of Cardiology, 2035 Route des Colles, 06903 Sophia Antipolis, France. 4. Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Avenue de la République, 37170 Tours, France. 5. Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBER-CV, Ctra. Madrid-Cartagena, 30120 El Palmar, Murcia, Spain. 6. Department of Cardiology, Ludwig-Maximilians-University, Geschwister-Scholl-Platz 1, 80539 Munich, Germany. 7. School of Medicine, Belgrade University, Studentski trg 1, Belgrade, Serbia. 8. Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia. 9. University of Medicine, 'Carol Davila', Colentina University Hospital, Soseaua Stefan cel Mare, Sector 2 19-21 Bucharest, Romania. 10. Department of Cardiology, Medical University of Silesia, Poniatowskiego 15, 40-055 Katowice, Poland. 11. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, S. Orsola-Malpighi University Hospital, Via Pietro Albertoni, 15, 40138 Bologna, Italy. 12. Maria Cecilia Hospital, GVM Care & Research, Ettore Sansavini Health Science Foundation, Via Corriera 1, 48033 Cotignola, Italy. 13. ANMCO Research Center, Via La Marmora 34, 50121 Firenze, Italy. 14. Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark.
Abstract
Aims: Contemporary data regarding atrial fibrillation (AF) management and current use of oral anticoagulants (OACs) for stroke prevention are needed. Methods and results: The EURObservational Research Programme on AF (EORP-AF) Long-Term General Registry analysed consecutive AF patients presenting to cardiologists in 250 centres from 27 European countries. From 2013 to 2016, 11 096 patients were enrolled (40.7% female; mean age 69 ± 11 years). At discharge, OACs were used in 9379 patients (84.9%), with non-vitamin K antagonists (NOACs) accounting for 40.9% of OACs. Antiplatelet therapy alone was used by 20% of patients, while no antithrombotic treatment was prescribed in 6.4%. On multivariable analysis, age, hypertension, previous ischaemic stroke, symptomatic AF and planned cardioversion or ablation were independent predictors of OAC use, whereas lone AF, previous haemorrhagic events, chronic kidney disease and admission for acute coronary syndrome (ACS) or non-cardiovascular causes independently predicted OAC non-use. Regarding the OAC type, coronary artery disease, history of heart failure, or valvular heart disease, planned cardioversion and non-AF reasons for admission independently predicted the use of vitamin K antagonists (VKAs). Wide variability among the European regions was observed in the use of NOACs, independently from other clinical factors. Conclusion: The EORP-AF Long-Term General Registry provides a full picture of contemporary use of OAC in European AF patients. The overall rate of OACs use was generally high (84.9%), and a series of factors were associated with the prescription of OAC. A significant geographical heterogeneity in prescription of NOACs vs. VKAs was evident.
Aims: Contemporary data regarding atrial fibrillation (AF) management and current use of oral anticoagulants (OACs) for stroke prevention are needed. Methods and results: The EURObservational Research Programme on AF (EORP-AF) Long-Term General Registry analysed consecutive AFpatients presenting to cardiologists in 250 centres from 27 European countries. From 2013 to 2016, 11 096 patients were enrolled (40.7% female; mean age 69 ± 11 years). At discharge, OACs were used in 9379 patients (84.9%), with non-vitamin K antagonists (NOACs) accounting for 40.9% of OACs. Antiplatelet therapy alone was used by 20% of patients, while no antithrombotic treatment was prescribed in 6.4%. On multivariable analysis, age, hypertension, previous ischaemic stroke, symptomatic AF and planned cardioversion or ablation were independent predictors of OAC use, whereas lone AF, previous haemorrhagic events, chronic kidney disease and admission for acute coronary syndrome (ACS) or non-cardiovascular causes independently predicted OAC non-use. Regarding the OAC type, coronary artery disease, history of heart failure, or valvular heart disease, planned cardioversion and non-AF reasons for admission independently predicted the use of vitamin K antagonists (VKAs). Wide variability among the European regions was observed in the use of NOACs, independently from other clinical factors. Conclusion: The EORP-AF Long-Term General Registry provides a full picture of contemporary use of OAC in European AFpatients. The overall rate of OACs use was generally high (84.9%), and a series of factors were associated with the prescription of OAC. A significant geographical heterogeneity in prescription of NOACs vs. VKAs was evident.
Authors: Michael G Fradley; Kerry Ellenberg; Mohammed Alomar; Justin Swanson; Anant Kharod; Anh Thy H Nguyen; Sara Khodor; Shreya Mishra; Linh M Duong; Nirav Shah; Merna Armanious; Isaac B Rhea; Matthew B Schabath; Kevin E Kip Journal: JACC CardioOncol Date: 2020-12-15
Authors: P P Olimpieri; A Di Lenarda; F Mammarella; L Gozzo; A Cirilli; M Cuomo; M M Gulizia; F Colivicchi; G Murri; D Gabrielli; F Trotta Journal: Int J Cardiol Heart Vasc Date: 2020-01-23
Authors: Steven A Lubitz; Shaan Khurshid; Lu-Chen Weng; Gheorghe Doros; Joseph Walker Keach; Qi Gao; Anil K Gehi; Jonathan C Hsu; Matthew R Reynolds; Mintu P Turakhia; Thomas M Maddox Journal: Am Heart J Date: 2018-03-10 Impact factor: 4.749
Authors: Monika Kozieł; Stefan Simovic; Nikola Pavlovic; Milan Nedeljkovic; Vilma Paparisto; Ljilja Music; Evgenii Goshev; Anca Rodica Dan; Sime Manola; Zumreta Kusljugic; Elina Trendafilova; Dobromir Dobrev; Gheorghe-Andrei Dan; Gregory Y H Lip; Tatjana S Potpara Journal: Int J Cardiol Heart Vasc Date: 2019-12-28